Navigation Links
Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
Date:5/20/2013

WOBURN, Mass., May 20, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies.

Prior to joining Flexion, Mr. Driscoll was chief financial officer for Novavax (NASDAQ: NVAX) where he led a team that secured more than $250 million through a combination of investment funding and commercial and government contracts. He was also instrumental in increasing Novavax' institutional shareholder base, expanding analyst coverage and implementing numerous financial reforms that strengthened that company's position. Prior to Novavax, Mr. Driscoll served as chief financial officer and subsequently chief executive officer of publicly-traded Genelabs, chief financial officer of private company Astraris and chief executive officer of OXiGENE.

"We are delighted to add a leader of Fred's experience and expertise to our team as we continue to focus on increasing investor value while advancing our pipeline of sustained release, intra-articular osteoarthritis medicines," said Michael Clayman , M.D., chief executive officer of Flexion. "With Phase 2b data for our lead compound on the horizon, we are confident that Fred will play an important role in the future of the company."

Mr. Driscoll holds a bachelor's degree in accounting and finance from Bentley University in Waltham, Mass.

About Flexion TherapeuticsFlexion is a clinical-stage specialty pharmaceutical company developing innovative therapeutics for musculoskeletal disorders. In our efforts to provide products with superior efficacy and safety,
'/>"/>

SOURCE Flexion Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
6. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
7. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
8. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
9. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
10. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
11. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Nev. , Sept. 17, 2014  PDL BioPharma, Inc. ... its independent registered accounting firm, Ernst & Young LLP ("EY") ... was confirmed in a letter delivered to the Company on ... on September 16, 2014.  PDL has issued ... "We have received a number of inquiries on the reason ...
(Date:9/17/2014)... PRINCETON, N.J. , Sept. 17, 2014 /PRNewswire/ ... developing targeted therapeutic devices to address infectious disease, cancer ... Sciences, Inc. (ESI), disclosed today that each company will ... Summit. On September 18 th , ... presentation entitled: "Exosomes: A Multiplexed Platform for Clinical Management." ...
(Date:9/17/2014)... NEWTOWN, Pa. , Sept. 17, 2014 ... services and eClinical Solutions, today announced three of its ... Conference for Clinical Data Management to be held ... Vegas, Nevada . The Company also announced the ... to raise overall quality in clinical trials acquired earlier ...
(Date:9/17/2014)... 2014 Alternative Fuels Americas, Inc. (AFAI) announced today ... Purpose Vehicle in partnership with Jatro Greentech, Inc., a ... The SPV shall be called AFAI Jatro Green Ethiopia and ... shareholder. The SPV shall pursue Jatropha planting and biofuels production ... Ethiopia . "Although we have experienced ...
Breaking Biology Technology:PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3
... U.S. ... business, BOSTON, MA ... Hand, the world,s first commercially,available bionic hand, today announced that it has ... the,United States., Bill Graham has been named U.S. sales manager for ...
... PLC Systems Inc.,(Amex: PLC ) today announced that ... Conference on February 18-21, 2008 at the Ritz,Carlton Laguna Niguel ... 20th beginning at 3:30 pm local time. Presenting for the ... webcast of the presentation will be available at the company,s,website ...
... Open DICOM Standard DR and Data Management Systems Spurs ... Forty-Five Percent Growth for Company, ... a,leading developer of digital radiography (DR), PACS (Picture Archiving and,Communications ... the company,s revenues grew 45 percent,to surpass $35 million for ...
Cached Biology Technology:Touch Bionics adds to sales, marketing, production and design teams 2Touch Bionics adds to sales, marketing, production and design teams 3PLC Systems to Present at the ROTH Conference 2Eklin Medical Reports Record Revenues for 2007 2Eklin Medical Reports Record Revenues for 2007 3
(Date:9/18/2014)... people are too stressed they are often grouchy, grumpy, ... Institute (BMI) at EPFL have just highlighted a fundamental ... and the loss of social skills and cognitive impairment. ... regulatory molecule in the brain. This was revealed by ... , Carmen Sandi,s team went to look for answers ...
(Date:9/17/2014)... reproductive technologies, the justice and well-being of our ... identify key issues, articulate their values and concerns, ... defensible ways forward. But what are the best ... Hastings Center and the Presidential Commission for the ... publish a series of essays to highlight the ...
(Date:9/17/2014)... A rare genetic disorder known as Jacobsen syndrome has ... investigation by researchers at San Diego State University and ... suggesting better treatment options for people with Jacobsen syndrome, ... underpinnings of autism., Jacobsen syndrome affects approximately 1 in ... It occurs in a person when there is a ...
Breaking Biology News(10 mins):How stress tears us apart 2Why bioethics literacy matters 2Why bioethics literacy matters 3A link between Jacobsen syndrome and autism 2
... Scientists across the world are building an extensive repository ... understanding the function of the approximately 57,000 genes that ... Rice Functional Genomics Consortium recently announced the public availability ... mutations in about half of the known functional genes ...
... people are affected with retinitis pigmentosa (RP), a disease ... blindness. Now, a University of Missouri researcher has identified ... different forms of RP. This discovery will help scientists ... humans. "The same genetic mutations ...
... WASHINGTON, DC As researchers continue to examine ... ,important that people understand the differences among various ... Corn Refiners Association (CRA). Interchanging two distinctly different ... corn syrup, creates factually incorrect conclusions and misleads ...
Cached Biology News:200,000 rice mutants available worldwide for scientific investigation 2Cats' eye diseases genetically linked to diseases in humans 2Pure fructose frequently confused with high fructose corn syrup 2